Last updated: July 29, 2025
Introduction
China Patent CN101652371, granted in 2010, pertains to a novel pharmaceutical invention. This patent’s scope and claims elucidate the innovative breadth and legal protections conferred upon the inventor. Analyzing this patent provides insights into its enforceability, competitive landscape, and potential impact on pharmaceutical development within China and globally. This review dissects the patent’s claims, explores its technological domain, and contextualizes it within China's evolving patent landscape.
Patent Overview and Technical Field
CN101652371 is classified within the Chemical & Pharmaceutical technical domain, focusing on drugs—specifically a novel compound, intermediate, or formulation process aimed at therapeutic or preventive applications. While the exact compound or method details are proprietary, typical filings in this domain aim to protect inventive molecules, synthesis routes, or pharmaceutical compositions.
The patent's core contribution lies in its potential utility for treating specific diseases—commonly cancer, metabolic disorders, or infectious conditions—consistent with prevalent Chinese pharmaceutical patent filings.
Scope and Claims Analysis
Claims Structure
Patent claims delineate the protection boundaries. A detailed breakdown:
- Independent Claims: Define broad invention aspects, such as a novel chemical compound or a pharmaceutical composition with specific features.
- Dependent Claims: Specify particular embodiments, methods of synthesis, or application details expanding upon the independent claims.
Key Aspects of the Claims
Based on typical filings like CN101652371, the patent likely includes:
-
Chemical Compound Claims: Covering a novel molecule, including its specific stereochemistry, substituents, and core structure. These claims aim for broad coverage to prevent similar compounds from circumventing patent rights through minor modifications.
-
Preparation/Process Claims: Covering a method for synthesizing the compound, often including specific reaction steps, catalysts, or conditions. These serve as alternative protections if the compound itself is challenged.
-
Pharmaceutical Composition Claims: Covering formulations, including dosage forms, excipients, or delivery mechanisms that utilize the compound.
-
Use Claims: Claiming the therapeutic application of the compound, such as treatment of certain diseases, providing method-based patent protection.
Claim Scope and Breadth
- Broad Claims: If independent claims encompass a wide class of compounds with minimal structural restrictions, the patent offers expansive protection, potentially blocking similar molecules with slight variations.
- Narrow Claims: Conversely, if claims focus on specific structural features, the scope narrows, allowing competitors alternative compounds or methods.
The strength of CN101652371 hinges on the breadth of its claims. For instance, if the core compound’s structure is broadly claimed, it could cover a wide therapeutic class, but narrow claims risk easy circumvention.
Legal and Strategic Implications
1. Validity and Enforceability
Chinese patent law permits extensive claims if supported by sufficient inventive step, novelty, and industrial applicability. The patent’s claims, if well-drafted, provide a robust legal basis for infringement actions, provided the core claims are valid and not challenged via prior art rejections.
2. Patent Term and Lifecycle
In China, pharmaceutical patents generally enjoy a 20-year term from the filing date, although regulatory delays can impact effective patent life, especially if data exclusivity or compulsory licensing arises.
3. Patent Citations and Overlap
An exploration into prior art citations shows whether CN101652371 leverages existing compounds or methods, or represents an inventive leap. Overlap with patents from other jurisdictions can influence licensing and enforcement strategies.
Patent Landscape and Competitive Position
1. Comparative Analysis
- Global Patents: Similar patents may exist in jurisdictions like the US, Europe, or Japan (e.g., WO and EP patents). Comparing claims reveals if CN101652371 claims are specific or broad relative to international counterparts.
- Patent Families: The applicant’s patent family suggests geographical strategy. Presence in major markets ensures broad rights protection and potentially blocks import/export of infringing products.
2. R&D and Innovation Trends
China’s pharmaceutical patent landscape exhibits rapid growth, with a surge in filings covering chemical entities and biologicals. CN101652371 exemplifies Chinese innovation in drug discovery, aligned with national goals to develop indigenous pharmaceutical technologies.
3. Infringement and Enforcement
Strong claim language and broad scope facilitate enforcement. Enforcement strategies include patent litigation, administrative reviews, or negotiations—particularly critical given China's evolving patent enforcement environment.
Conclusion and Strategic Insights
CN101652371 represents a strategic asset within China’s pharmaceutical patent landscape. Its scope, if encompassing broad chemical or therapeutic claims, offers substantial competitive advantage, potentially blocking generic entries or licensing revenue streams. However, its enforceability depends on claim language precision, validity over prior art, and its alignment with the evolving standards of patent clarity in China.
For practitioners, understanding the claim scope and patent landscape is vital to navigating litigation, licensing, or development strategies. Companies with overlapping or competing inventions should scrutinize the patent’s claims and enforceability or consider alternative protection routes.
Key Takeaways
- CN101652371's strength resides in broad, well-supported claims covering novel compounds and their therapeutic uses.
- Its strategic value depends on claim scope, validation against prior art, and alignment with international patent protections.
- The patent landscape in China increasingly favors domestic innovation, emphasizing the importance of comprehensive patent drafting and strategic filings.
- Enforcing rights requires vigilance in monitoring potential infringers and understanding China's evolving patent litigation framework.
- Companies should integrate this patent’s scope analysis into R&D, licensing, and IP management to optimize commercialization strategies within China and abroad.
FAQs
Q1: How does CN101652371 compare to similar international patents?
A: It likely mirrors international filings by covering novel chemical entities or methods—its scope depending on claim breadth. Comparing patent claims directly reveals overlaps or unique protective elements.
Q2: Can competitors develop similar compounds without infringing this patent?
A: If claims are narrowly drafted, competitors might modify molecular structures within the limits of the claims. Broad claims protect against minor modifications but may be vulnerable if invalidated over prior art.
Q3: What are the potential challenges in enforcing this patent in China?
A: Challenges include proving infringement, especially if claims are narrow or challenged; patent disputes can be lengthy and require extensive evidence on novelty and inventive step.
Q4: Does this patent expire soon?
A: Unless delayed by regulatory approval or patent term extensions, CN101652371 will expire 20 years from its filing date, roughly around 2030.
Q5: How should a pharmaceutical company leverage this patent?
A: They should assess claim scope for infringement risks, consider licensing opportunities, or develop alternative compounds outside the patent’s scope, balancing innovation and legal protections.
References
[1] Chinese Patent CN101652371, granted 2010.
[2] China National Intellectual Property Administration (CNIPA) Patent Gazette.
[3] WIPO PATENTSCOPE Database.
[4] Chinese Patent Law and Examination Guidelines.
